Johnson & Johnson has evidence that the benefits of dual treatment with the firm’s EGFR/MET inhibitor Rybrevant (amivantamab) and EGFR inhibitor Lazcluze (lazertinib) improve over time from updated results from the Phase III MARIPOSA clinical trial of the two-drug combination versus AstraZeneca PLC’s standard-of-care EGFR inhibitor Tagrisso (osimertinib) in first-line non-small cell lung cancer (NSCLC) with EGFR mutations.
Key Takeaways
-
Updated results from the Phase III MARIPOSA study of Johnson & Johnson’s newly approved Rybrevant/Lazcluze combination regimen for first-line treatment of EGFR-mutant NSCLC showed that benefits relative to Tagrisso monotherapy continued to improve over time.
-
The company has worked through safety and tolerability concerns with VTE and infusion-related reaction prophylaxis and a subcutaneous version of Rybrevant pending at the US FDA
The US Food and Drug Administration approved Rybrevant plus Lazcluze for first-line treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations on 20 August. The latest MARIPOSA results, from a late-breaking oral presentation on 8 September at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer (WCLC) in San Diego, revealed that overall survival (OS) was not estimable yet for patients treated with the J&J drug combination, but it was estimated at 37.3 months for Tagrisso (HR=0.77, p=0.019)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?